Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

医学 慢性阻塞性肺病 哮喘 内科学 安慰剂 养生 临床终点 临床试验 物理疗法 病理 替代医学
作者
Klaus Friedrich Rabe,Bartolomé R. Celli,Michael E. Wechsler,Raolat M. Abdulai,Xiaodong Luo,Maarten M. Boomsma,Heribert W. Staudinger,Julie E. Horowitz,Aris Baras,Manuel A. R. Ferreira,Marcella K. Ruddy,Michael C. Nivens,Nikhil Amin,David M. Weinreich,George D. Yancopoulos,Hélène Goulaouic
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (11): 1288-1298 被引量:248
标识
DOI:10.1016/s2213-2600(21)00167-3
摘要

Summary

Background

Genetic data implicate IL-33 in asthma susceptibility. Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD). In this study we first aimed to test the hypothesis that genetic variants in the IL-33 pathway were also associated with COPD. On the basis of the strong association of IL-33 pathway genes with pulmonary diseases like asthma and COPD, we conducted this phase 2a trial to assess the safety and efficacy of itepekimab in patients with moderate-to-severe COPD on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy.

Methods

In this two-part study, genetic analyses of loss-of-function and gain-of-function variants in the IL-33 pathway, previously associated with asthma risk, were initially characterised for COPD. We then did a double-blind, phase 2a trial comparing itepekimab with placebo in patients with moderate-to-severe COPD despite standard therapy, at 83 study sites in ten countries. Patients aged 40–75 years who were current or former smokers, had been diagnosed with COPD for at least 1 year, and were on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy, were randomly assigned (1:1) to receive itepekimab 300 mg or placebo, administered as two subcutaneous injections every 2 weeks for 24–52 weeks. The primary endpoint of the phase 2a trial was annualised rate of moderate-to-severe acute exacerbations of COPD during the treatment period. The key secondary outcome was change in prebronchodilator FEV1 from baseline to weeks 16–24. Prespecified subgroup analyses were done for each of the endpoints, including by smoking status. Efficacy and safety analyses were done in all participants who received at least one dose of assigned treatment (modified intention-to-treat population). This trial is registered at ClinicalTrials.gov (NCT03546907).

Findings

Genetic analyses demonstrated association of loss of function in IL33 with reduced COPD risk, and gain of function in IL33 and IL1RL1 variants with increased risk. Subsequent to this, in the phase 2 trial, 343 patients were randomly assigned to placebo (n=171) or itepekimab (n=172) from July 16, 2018, to Feb 19, 2020. Annualised rates of acute exacerbations of COPD were 1·61 (95% CI 1·32–1·97) in the placebo group and 1·30 (1·05–1·61) in the itepekimab group (relative risk [RR] 0·81 [95% CI 0·61–1·07], p=0·13), and least squares mean prebronchodilator FEV1 change from baseline to weeks 16–24 was 0·0 L (SD 0·02) and 0·06 L (0·02; difference 0·06 L [95% CI 0·01–0·10], p=0·024). When analysis was restricted to former smokers, treatment with itepekimab was associated with nominally significant reductions in acute exacerbations of COPD (RR 0·58 [95% CI 0·39–0·85], p=0·0061) and FEV1 improvement (least squares mean difference 0·09 L [0·02–0·15], p=0·0076) compared with placebo. Current smokers treated with itepekimab showed no treatment benefit versus placebo for exacerbations (RR 1·09 [0·74–1·61], p=0·65) or FEV1 (least squares mean difference 0·02 [−0·05 to 0·09], p=0·54). Treatment-emergent adverse events (TEAEs) occurred in 135 (78%) patients in the itepekimab group and 136 (80%) in the placebo group. The most common TEAEs were nasopharyngitis (28 [16%] in the itepekimab group vs 29 [17%] in the placebo group), bronchitis (18 [10%] vs 14 [8%]), headache (14 [8%] vs 23 [13%]), and upper respiratory tract infection (13 [8%] vs 15 [9%]).

Interpretation

The primary endpoint in the overall population was not met, subgroup analysis showed that itepekimab reduced exacerbation rate and improved lung function in former smokers with COPD. Two phase 3 clinical studies are ongoing to confirm the efficacy and safety profile of itepekimab in former smokers with COPD.

Funding

Sanofi and Regeneron Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
火星上的果汁完成签到,获得积分10
1秒前
jane完成签到 ,获得积分10
1秒前
淡定沛珊完成签到,获得积分10
1秒前
Davidjun完成签到,获得积分10
1秒前
赵念婉完成签到,获得积分10
1秒前
欧阳月空完成签到,获得积分10
2秒前
研友_5Z4ZA5完成签到,获得积分10
2秒前
2秒前
Supine.发布了新的文献求助10
2秒前
幸福慕灵完成签到,获得积分10
2秒前
3秒前
我是老大的应助被江户川采纳,获得10
3秒前
爱你沛沛完成签到 ,获得积分10
3秒前
YL发布了新的文献求助10
4秒前
keyIncy完成签到,获得积分10
4秒前
wpf完成签到 ,获得积分10
4秒前
天马行空完成签到,获得积分10
4秒前
苹果树下的懒洋洋完成签到 ,获得积分10
4秒前
英俊的铭的应助被谨慎的夏槐采纳,获得10
4秒前
晶晶完成签到,获得积分10
5秒前
18岁的王教授完成签到,获得积分10
5秒前
王鹏斐完成签到,获得积分10
6秒前
Ethan完成签到,获得积分10
6秒前
xxz发布了新的文献求助10
6秒前
新野完成签到,获得积分10
6秒前
辛勤月饼完成签到,获得积分10
6秒前
笑笑笑笑笑完成签到,获得积分10
7秒前
小胡完成签到,获得积分10
7秒前
7秒前
俭朴蜜粉完成签到,获得积分10
7秒前
7秒前
佳佳完成签到 ,获得积分10
8秒前
8秒前
干净老姆完成签到,获得积分10
8秒前
哈基根向上完成签到 ,获得积分10
8秒前
zz完成签到,获得积分10
8秒前
吃不庞女士完成签到,获得积分10
8秒前
MM完成签到,获得积分20
8秒前
飞翔的荷兰人完成签到,获得积分10
8秒前
取个昵称不容易给取个昵称不容易的求助进行了留言
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808